Somerville Kurt F Has $5.97 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Somerville Kurt F reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,064 shares of the medical instruments supplier's stock after selling 5,716 shares during the quarter. Somerville Kurt F's holdings in Becton, Dickinson and Company were worth $5,970,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Smallwood Wealth Investment Management LLC acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth $27,000. REAP Financial Group LLC increased its position in Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares during the period. Alpine Bank Wealth Management purchased a new position in Becton, Dickinson and Company in the first quarter worth $29,000. Cornerstone Planning Group LLC lifted its stake in shares of Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 99 shares during the period. Finally, Nexus Investment Management ULC purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $34,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BDX shares. Bank of America cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective on the stock. in a research note on Thursday, May 1st. Morgan Stanley decreased their price target on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Wall Street Zen downgraded Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Piper Sandler cut Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $260.00 to $185.00 in a report on Friday, May 2nd. Finally, Citigroup downgraded Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their target price for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of "Hold" and an average price target of $219.22.

Becton, Dickinson and Company Stock Performance

BDX traded up $1.04 during trading hours on Thursday, hitting $183.62. 1,801,451 shares of the stock were exchanged, compared to its average volume of 2,985,697. The stock has a market cap of $52.63 billion, a price-to-earnings ratio of 35.04, a price-to-earnings-growth ratio of 1.38 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The stock has a 50-day simple moving average of $173.87 and a 200-day simple moving average of $203.40. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.17 EPS. Analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.27%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Shan sold 1,166 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president owned 4,575 shares in the company, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.